Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 1
2010 3
2011 1
2013 1
2014 3
2015 1
2016 2
2017 2
2018 4
2019 2
2020 5
2021 8
2022 7
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators. Cappellini MD, et al. N Engl J Med. 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182. N Engl J Med. 2020. PMID: 32212518 Clinical Trial.
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Taher AT, Cappellini MD, Kattamis A, Voskaridou E, Perrotta S, Piga AG, Filosa A, Porter JB, Coates TD, Forni GL, Thompson AA, Tartaglione I, Musallam KM, Backstrom JT, Esposito O, Giuseppi AC, Kuo WL, Miteva D, Lord-Bessen J, Yucel A, Zinger T, Shetty JK, Viprakasit V; BEYOND Investigators. Taher AT, et al. Lancet Haematol. 2022 Oct;9(10):e733-e744. doi: 10.1016/S2352-3026(22)00208-3. Epub 2022 Aug 22. Lancet Haematol. 2022. PMID: 36007538 Clinical Trial.
Interaction of Transfusion and Iron Chelation in Thalassemias.
Porter JB, Garbowski MW. Porter JB, et al. Among authors: garbowski mw. Hematol Oncol Clin North Am. 2018 Apr;32(2):247-259. doi: 10.1016/j.hoc.2017.11.010. Hematol Oncol Clin North Am. 2018. PMID: 29458730 Free article. Review.
The pathophysiology of transfusional iron overload.
Porter JB, Garbowski M. Porter JB, et al. Among authors: garbowski m. Hematol Oncol Clin North Am. 2014 Aug;28(4):683-701, vi. doi: 10.1016/j.hoc.2014.04.003. Hematol Oncol Clin North Am. 2014. PMID: 25064708 Review.
The community ecology perspective of omics data.
Jurburg SD, Buscot F, Chatzinotas A, Chaudhari NM, Clark AT, Garbowski M, Grenié M, Hom EFY, Karakoç C, Marr S, Neumann S, Tarkka M, van Dam NM, Weinhold A, Heintz-Buschart A. Jurburg SD, et al. Among authors: garbowski m. Microbiome. 2022 Dec 13;10(1):225. doi: 10.1186/s40168-022-01423-8. Microbiome. 2022. PMID: 36510248 Free PMC article.
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
Porter J, Taher A, Viprakasit V, Kattamis A, Coates TD, Garbowski M, Dürrenberger F, Manolova V, Richard F, Cappellini MD. Porter J, et al. Among authors: garbowski m. Expert Rev Hematol. 2021 Jul;14(7):633-644. doi: 10.1080/17474086.2021.1935854. Epub 2021 Jul 29. Expert Rev Hematol. 2021. PMID: 34324404 Review.
39 results